Senator Targets Merck’s Drug Pricing | Concord News

Senator Maggie Hassan is launching a formal investigation into Merck’s pricing and patent strategies for one of its most expensive drugs, costing patients nearly $200,000 annually. Suspecting the company is using “patent shield” tactics to block competition and keep prices artificially high, Hassan is prepared to introduce new legislation if Merck doesn’t voluntarily reform its practices. Her office has begun gathering documents to uncover how Merck manages patents and pricing — a move that underscores growing national concern over the affordability of life-saving medications. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/176b293e609a4b8f